VERAXA Biotech AG (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener brings over three decades of international financial leadership experience spanning global capital markets, investment banking, corporate finance, asset management, and strategic leadership. He will report to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to play a pivotal role in supporting the company's capital strategy, strategic opportunities, and the continued development of its proprietary BiTAC(R) technology platform and oncology pipeline.
Willener's appointment comes at a critical juncture for VERAXA as it advances its pipeline of bispecific T cell engagers, bispecific ADCs, and other innovative antibody formats. His extensive background in capital markets and corporate finance is likely to be instrumental in navigating the complexities of funding clinical development and potential partnerships. Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG before being appointed CFO in 2025, where he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing areas including corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management.
This strategic hire underscores VERAXA's commitment to building a robust financial foundation to support its ambitious research and development goals. The company's BiTAC(R) technology, which stands for bispecific T cell engager with antibody-like characteristics, represents a promising approach in the fight against cancer. By leveraging the power of the immune system, BiTACs aim to direct T cells to specifically target and eliminate tumor cells, potentially offering more effective and safer treatment options compared to conventional therapies.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. This strong scientific heritage, combined with the addition of a seasoned financial executive, positions the company well for its next phase of growth. The appointment of Willener is expected to enhance investor confidence and provide the strategic financial oversight necessary to advance VERAXA's pipeline from discovery to clinical development and beyond.
As VERAXA continues to develop its proprietary BiTAC(R) technology and expand its oncology pipeline, the role of the CFO becomes increasingly vital. Willener's proven track record in managing large investment portfolios and leading financial strategies in both public and private settings aligns with the company's objectives. His expertise will be crucial in evaluating strategic opportunities, optimizing capital allocation, and communicating the company's value proposition to the investment community.
The news of Willener's appointment is a positive signal for VERAXA's future, indicating a focused effort on strengthening its financial and strategic capabilities. Investors and industry observers will be watching closely to see how this leadership change translates into tangible progress for the company's innovative cancer therapies. With a robust financial leader in place, VERAXA is better equipped to navigate the challenging landscape of biotech development and ultimately deliver on its mission to provide next-generation treatments for patients in need.
